Lactococcus Lactis As a Live Vector for Mucosal Delivery of Therapeutic Proteins

Overview

Journal Hum Vaccin

Specialty Allergy & Immunology

Date 2009 Feb 10

PMID 19202351

Citations 38

Authors

Luis G Bermudez-Humaran

Affiliations

Soon will be listed here.

Abstract

Food-grade lactic acid bacteria (LAB) have been safely consumed by humans for centuries in fermented foods. Lactococcus lactis, a LAB widely used in the dairy industry as a starter, can be genetically engineered to efficiently produce a large variety of proteins. This feature has been recently exploited by scientists for the development of a new generation of vectors to deliver therapeutic proteins to the mucosal tissues. The successful Phase I clinical trial with a L. lactis strain secreting interleukin-10 for Crohn's disease has opened new horizons for the use of genetically engineered LAB as delivery vehicles. This commentary reviews the current advances made with L. lactis as live vector for the mucosal delivery of therapeutic proteins.

Citing Articles

Recombinant lactic acid bacteria as promising vectors for mucosal vaccination.

Qiao N, Du G, Zhong X, Sun X Exploration (Beijing). 2023; 1(2):20210026.

PMID: 37323212 PMC: 10191043. DOI: 10.1002/EXP.20210026.

Vaccination with recombinant Lactococcus lactis expressing HA1-IgY Fc fusion protein provides protective mucosal immunity against H9N2 avian influenza virus in chickens.

Zhang R, Xu T, Li Z, Li L, Li C, Li X Virol J. 2023; 20(1):76.

PMID: 37085816 PMC: 10119832. DOI: 10.1186/s12985-023-02044-9.

Auxotrophic Expressing Porcine Rotavirus VP4 Constructed Using CRISPR-Cas9D10A System Induces Effective Immunity in Mice.

Zhang H, Zhao H, Zhao Y, Sui L, Li F, Zhang H Vaccines (Basel). 2022; 10(9).

PMID: 36146587 PMC: 9504633. DOI: 10.3390/vaccines10091510.

Use of genetically modified lactic acid bacteria and bifidobacteria as live delivery vectors for human and animal health.

Levit R, Cortes-Perez N, de Moreno de LeBlanc A, Loiseau J, Aucouturier A, Langella P Gut Microbes. 2022; 14(1):2110821.

PMID: 35960855 PMC: 9377234. DOI: 10.1080/19490976.2022.2110821.

Harnessing the potential of species for therapeutic delivery at the lumenal-mucosal interface.

Spangler J, Caruana J, Medintz I, Walper S Future Sci OA. 2021; 7(4):FSO671.

PMID: 33815818 PMC: 8015674. DOI: 10.2144/fsoa-2020-0153.